On November 27, 2024, the National Finals of the 13th China Innovation and Entrepreneurship Competition Disruptive Technology Innovation Competition hosted by the Ministry of Industry and Information Technology came to a successful conclusion in Hangzhou.

It is reported that this event has 169 high-quality projects with disruptive potential from six major future industry competitions, including future manufacturing, future information, future materials, future energy, future space, and future health. The final will hold a peak showdown. Relying on its excellent "disruptive" innovation and "hard technology" strength, Yuanvore Medicine finally won the [Excellence Award] for its R & D project "Development of Engineered i-MSCs Cell Drugs for the Treatment of Osteoarthritis".

Yuanvore Medicine is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. iPSC technology, known as the third medical revolution after drug treatment and surgical treatment, not only shows great potential in the treatment of chronic degenerative diseases, but also has disruptive innovative significance.

Ouyang Ping, founder and chairman of Yuanvore Medicine, said that this honor is not only a full recognition of the company's efforts in the fields of biomedicine and general health, but also a powerful spur to the company's continued innovation and development in the future. We will take this opportunity to continue to enhance our independent innovation capabilities, go all out to fight against key core technologies, and breed more revolutionary and disruptive technological achievements. At the same time, we will also accelerate the transformation of innovative products from laboratory to clinical, contribute more efficient and advanced treatment solutions to human health, and fulfill our mission and responsibilities with practical actions.

Innovation is the spirit of courage to pioneer and the power to subvert the shackles of tradition. The source of medical innovation is unmet clinical needs. Every technological breakthrough opens up a new space, opens up a new incremental market, and also brings new development opportunities and economic growth points to the medical and health industry.

Osteoarthritis (OA) is a chronic joint disease with a high incidence, long course and difficult treatment, causing great pain to patients. Based on the concept of "the right cells play the right function", this project innovatively applies engineering methods such as induced pluripotent stem cell technology, gene editing technology, and iPSC induced differentiation technology to differentiate iPSC into i-MSC through mesodermal neural crest cell lines. Intraarticular injection can correct the immune microenvironment and the morphology and function of chondrocytes in patients with OA, and finally complete the regenerative repair of OA, which can provide a rich universal source of cells. Currently, the proof of concept for R&D has been completed and the animal testing phase of preclinical research is underway.

Compared with traditional drugs, the subversive innovation of the engineered i-MSCs cell drugs developed in this project lies in:

1. As a MSCs drug, it can solve the problem that traditional chemical drugs cannot regenerate cartilage and reduce side effects; it can also solve the lack of autologous cartilage cells in immune regulation and inflammation relief;

2. Using reprogramming technology to build iPSCs and then induce and differentiate into i-MSCs can solve the problem of insufficient origin and poor consistency of adult-derived MSCs;

3. Engineered i-MSCs, which are obtained by gene editing the reprogrammed iPSC, can solve the problem of incorrect cartilage phenotypes of adult-derived MSCs and MSCs induced by iPSC traditional pathways, and have significant improvement in immune regulation and inflammation control.

Looking to the future, Yuanvore Medicine will continue to use the research and development of innovative technologies as the driving force, enhance the independent innovation capabilities of key core technologies, adhere to scientific exploration and clinical verification of breakthrough therapies, promote the birth and application of more disruptive technologies, and contribute to the innovation and development of the health industry in China and even the world. Contribute our wisdom and strength!

About the 13th China Innovation and Entrepreneurship Competition Disruptive Technology Innovation Competition

The 13th China Innovation and Entrepreneurship Competition Disruptive Technological Innovation Competition was hosted by the Torch High-Tech Industrial Development Center of the Ministry of Industry and Information Technology. As a national-level event, since its launch in August 2024, it has attracted more than a thousand technical projects from key universities, well-known scientific research institutes, industry leading enterprises and other units across the country to sign up for the competition. It aims to cultivate leading global enterprises and reshape The industrial competition pattern and promote future industrial development have laid a solid foundation, allowing more original and disruptive scientific and technological innovations to emerge, and using disruptive technologies and cutting-edge technologies to spawn new industries, new models, and new momentum. Develop new productive forces.

About Yuanvore Medicine

Shanghai Yuanvore Medicine Technology Co., Ltd. is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. It has applied for the world's leading independent intellectual property rights in three key areas: cell reprogramming, directed differentiation, and cell engineering. 36 items, including 11 invention patents, 5 of which have been authorized and 2 have applied for PCT, providing solutions for iPSC technology in regenerative medicine to treat chronic degenerative diseases.

In November 2024, Yuanvore Medicine and Shanghai City Sixth People's Hospital officially launched a metabolic disease cooperation project, which is also the first time in the world that iPSC technology has been applied to treat such diseases. In December, it reached a strategic cooperation with Dongfulong to jointly explore the world's leading full-scenario solution for the industrialization of iPSC technology.

"Yuan" is the beginning, and one yuan produces three;"Wu" soil is solid and heavy, giving birth to all things. Yuanvore Medicine uses stem cells as carriers, starts from the concept of "the right cells play the right function", uses small molecules to regulate cell fate, accurately obtains target phenotypic cells while improving target cell yield, and provides for the treatment of chronic degenerative diseases. Industrialized regenerative medicine solutions, and application empowerment to aging, degradation, damage and other major health fields, creating disruptive medical value and market value.